Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–34.

Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J cancer. 2011;105:1684–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of Non-Hodgkin’s Lymphoma. LID, Medical sciences (Basel, Switzerland) - https://doi.org/10.3390/medsci9010005.

van de Schans SAM, Issa DE, Visser O, Nooijen P, Huijgens PC, Karim-Kos HE, et al. Diverging trends in incidence and mortality, and improved survival of non-Hodgkin’s lymphoma, in the Netherlands, 1989–2007. Ann Oncol. 2012;23:171–82.

Article  PubMed  Google Scholar 

Durmaz M, Visser O, Posthuma EFM, Brouwer RE, Issa DE, de Jong D, et al. Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018. Blood Cancer J. 2022;12:38.

Wang Y, Shi Q, Shi ZY, Tian S, Zhang MC, Shen R, et al. Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma. Blood Adv. 2024;8:1587–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720–48.

Article  PubMed  PubMed Central  Google Scholar 

Project IN-HsLPF. A predictive model for aggressive non-Hodgkin’s lymphoma. N. Engl J Med. 2014;30:987–94.

Google Scholar 

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.

Article  CAS  PubMed  Google Scholar 

Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. J Clin Oncol. 2016;34:3150–6.

Article  CAS  PubMed  Google Scholar 

Zhou Z, Sehn LH, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42.

Borchmann P, Heger JM, Mahlich J, Papadimitrious MS, Riou S, Werner B. Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database. J Cancer Res Clin Oncol. 2023;149:7091–101.

Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl J Med. 2002;346:235–42.

Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116:2040–5.

Epperla N, Vaughn JL, Othus M, Hallack A, Costa LJ. Recent survival trends in diffuse large B-cell lymphoma-Have we made any progress beyond rituximab? Cancer Med. 2020;9:5519–25.

Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15:931–42.

Article  PubMed  Google Scholar 

Melchardt T, Egle A, Greil R. How I treat diffuse large B-cell lymphoma. ESMO open. 2023;8:100750.

Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015;170:504–14.

Article  PubMed  Google Scholar 

Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5:e609–17.

Article  PubMed  PubMed Central  Google Scholar 

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. 2022;386:351–63.

Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381:1817–26. 1474-547X (Electronic)

Article  CAS  PubMed  Google Scholar 

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 2013;14:525–33.

Article  CAS  PubMed  Google Scholar 

Issa DE, Dinmohamed AG, Wondergem MJ, Blommestein HM, Huijgens PC, Lugtenburg PJ, et al. A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands. Leuk Lymphoma. 2021;62:549–59.

Article  PubMed  Google Scholar 

Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–22.

Article  CAS  PubMed  Google Scholar 

Oerlemans S, Issa DE, van den Broek EC, Nijziel MR, Coebergh JW, Huijgens PC, et al. Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry. Ann Hematol. 2014;93:1705–15.

Article  CAS  PubMed  Google Scholar 

Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16.

Article  CAS  PubMed  Google Scholar 

Wästerlid T, Biccler JL, Brown PN, Bøgsted M, Enblad G, Mészáros Jørgensen J, et al. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study. Ann Oncol. 2018;29:1882–3.

Article  PubMed  Google Scholar 

Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. 2011;12:460–8.

Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:649–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nowakowski GS, Chiappella A, Witzig TE, Spina M, Gascoyne RD, Zhang L, et al. ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future Oncol. 2016;12:1553–63. 8301 (Electronic)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sehn LH. No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study. Blood. 2018;131:1629–30.

Article  CAS  PubMed  Google Scholar 

Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019;37:1285–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2018;36:2024–34.

Article  PubMed  Google Scholar 

werkgroep HL. Richtlijn diffuus grootcellig B-cel non-Hodgkin lymfoom. Hematologie NVv ed. 2021. https://hovon.nl/_asset/_public/TreatmentGuidelines/TreatmentGuidelines_Lymphoma/Richtlijn-DLBCL-_NVvH_2021.pdf.

Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA, Jager JJ. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol. 1993;22:369–76.

Article  CAS  PubMed  Google Scholar 

Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710–9.

Article  CAS  PubMed  Google Scholar 

Mohyuddin GR, Prasad V. Detecting Selection Bias in Observational Studies—When Interventions Work Too Fast. JAMA Intern Med. 2023;183:897–8.

Article  PubMed  Google Scholar 

Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivar Behav Res. 2011;46:399–424.

Article  Google Scholar 

Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661–79.

Article  PubMed  PubMed Central  Google Scholar